Susquehanna International Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-363,758
| Closed | -$8.77M | – | 13715 |
|
|
2023
Q1 | $8.77M | Buy |
363,758
+248,847
| +217% | +$3.12M | ﹤0.01% | 2631 |
|
|
2022
Q4 | $1.21M | Sell |
114,911
-68,229
| -37% | -$551K | ﹤0.01% | 5768 |
|
|
2022
Q3 | $824K | Buy |
183,140
+98,042
| +115% | +$447K | ﹤0.01% | 7143 |
|
|
2022
Q2 | $340K | Buy |
85,098
+31,400
| +58% | +$149K | ﹤0.01% | 9234 |
|
|
2022
Q1 | $393K | Sell |
53,698
-138,517
| -72% | -$828K | ﹤0.01% | 9588 |
|
|
2021
Q4 | $1.08M | Buy |
192,215
+101,739
| +112% | +$646K | ﹤0.01% | 7098 |
|
|
2021
Q3 | $579K | Sell |
90,476
-223,098
| -71% | -$1.43M | ﹤0.01% | 8999 |
|
|
2021
Q2 | $2.64M | Buy |
313,574
+65,460
| +26% | +$528K | ﹤0.01% | 5308 |
|
|
2021
Q1 | $2.6M | Buy |
248,114
+50,987
| +26% | +$717K | ﹤0.01% | 5291 |
|
|
2020
Q4 | $3.34M | Buy |
197,127
+42,281
| +27% | +$634K | ﹤0.01% | 4130 |
|
|
2020
Q3 | $1.99M | Buy |
154,846
+36,748
| +31% | +$464K | ﹤0.01% | 4638 |
|
|
2020
Q2 | $1.67M | Sell |
118,098
-240,503
| -67% | -$3.04M | ﹤0.01% | 4825 |
|
|
2020
Q1 | $3.3M | Buy |
358,601
+158,249
| +79% | +$2.04M | ﹤0.01% | 3137 |
|
|
2019
Q4 | $2.98M | Buy |
200,352
+158,266
| +376% | +$1.41M | ﹤0.01% | 3708 |
|
|
2019
Q3 | $287K | Buy |
42,086
+16,352
| +64% | +$165K | ﹤0.01% | 8388 |
|
|
2019
Q2 | $311K | Buy |
+25,734
| New | +$140K | ﹤0.01% | 8235 |
|
Other funds holding PRVB
Susquehanna International Group's PRVB Position: Q2 2023 in Review
Susquehanna International Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 363,758 shares — an estimated $8.77M sold.
Susquehanna International Group first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $8.77M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Susquehanna International Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Susquehanna International Group sold 363,758 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $8.77M.
- Susquehanna International Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Susquehanna International Group's Provention Bio, Inc. Common Stock position peaked at $8.77M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.